BioAge Labs (BIOA) Gains from Investment Securities (2023 - 2026)

BioAge Labs has disclosed Gains from Investment Securities across 4 years of filings, most recently posting $107000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $107000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $947000.0 (up 2267.5% YoY), and the FY2025 annual result was $7.9 million, up 46.99% from the prior year.
• Gains from Investment Securities came in at $107000.0 for Q1 2026 at BioAge Labs, down from $800000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $8.1 million in Q3 2025 to a low of -$282000.0 in Q2 2024.
• The 4-year median for Gains from Investment Securities is $307000.0 (2023), against an average of $1.6 million.
• Across the five-year window, Gains from Investment Securities slumped 86.97% in 2024 and jumped 1900.0% in 2025, its largest moves.
• BioAge Labs' Gains from Investment Securities stood at $307000.0 in 2023, then plunged by 86.97% to $40000.0 in 2024, then surged by 1900.0% to $800000.0 in 2025, then slumped by 86.62% to $107000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $107000.0 (Q1 2026), $800000.0 (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.